Nobel medicine prize goes to Deisseroth, Hegemann and Nagel for optogenetics

The Nobel Assembly at Karolinska Institutet awarded the 2026 Nobel Prize in Physiology or Medicine on Monday, 5 October, to Karl Deisseroth, Peter Hegemann and Georg Nagel. The citation is short: "for their discoveries concerning light-gated ion channels and optogenetics." The prize is 12 million Swedish kronor, to be shared equally. Deisseroth is at the Howard Hughes Medical Institute and Stanford University. Hegemann is at Humboldt University of Berlin. Nagel is at the University of Würzburg.

The award is for a method, not a drug. Optogenetics lets a researcher turn a chosen nerve cell on or off with light, in a living brain, while leaving the cells around it alone. That is a different tool from an electrode, which cannot pick one cell type out of a circuit, and from a drug, which floods a region. The Assembly's press release put the claim in one line: the method makes it possible to show how nerve cells shape memories, feelings and behaviours in the living brain.

An algal protein that opens in blue light

The protein came from a single-celled green alga, Chlamydomonas. Hegemann and Nagel found channelrhodopsin on the cell surface in the early 2000s. When blue light hits it, a channel through the protein opens. Charged ions flow in. The cell gets an electrical impulse. The useful surprise was portability. The two researchers found that the protein did the same job in cells that had never seen a pond. Put the gene in, shine blue light, and the cell became light-sensitive.

That finding sat for a few years as a piece of algal physiology. The medical use arrived when Deisseroth put the gene into nerve cells taken from rats. Blue light triggered a nerve signal. He published that result in 2005. Two years later, in 2007, he made the same switch work inside the brains of living mice. A fibre or an implanted light source could now drive a chosen set of neurons while the animal moved. The Assembly treats those two papers as the point at which a membrane protein became a method.

What laboratories actually do with it

Once the switch existed, labs used it to map circuits that older methods could only infer. The Nobel release says researchers have traced neural circuits that govern specific memories, feelings and behaviours tied to neurological and psychiatric disorders. The practical step is genetic. A virus carries the channelrhodopsin gene into one cell type, often under a promoter that only that type reads. Blue light then hits only those cells. If a behaviour appears or disappears, the circuit is implicated in a way a correlational scan cannot match.

The clinical line is narrower, and the Assembly is careful about it. Researchers are using the method in attempts to restore sight in people with visual impairment, by making remaining retinal cells respond to light. That is an attempt, not an approved therapy announced with this prize. The prize is for the discovery that made the attempt possible.

Per Svenningsson, chair of the Nobel Committee for Physiology or Medicine, said: "Optogenetics provides opportunities for mapping the brain in a way that we could once only dream of." The contact for the announcement was Pernilla Witte at Karolinska, and Thomas Perlmann, secretary-general of the Assembly.

Why this prize landed in 2026

Channelrhodopsin and the 2005 and 2007 papers are not new. Nobel committees often wait until a method has spread far enough that its use is no longer a claim by its inventors. Optogenetics is now a standard tool in systems neuroscience. Labs that study fear, thirst, parental behaviour, Parkinson's circuits and addiction routinely cite the same protein. The delay also let the committee see the clinical edge, the sight experiments, without having to pretend a treatment had already arrived.

The split of credit follows the split of the work. Hegemann and Nagel identified the channel and showed it could be moved between cells. Deisseroth turned it into a switch for neurons and then for the intact mouse brain. Equal shares of 12 million kronor treat those steps as one discovery. Readers who want the primary papers will find the 2005 neuron result and the 2007 in vivo result under Deisseroth's name, and the channelrhodopsin biochemistry under Hegemann and Nagel.

What the prize does not settle

A light-gated channel does not explain a disease. It lets someone test a circuit. Psychiatric diagnoses are still clinical categories, and a mouse that freezes when a fibre lights up is not a patient. The information gain in Monday's announcement is the chain itself: alga, blue-light channel, 2005 rat neurons, 2007 living mice, and a method now used to ask which cells carry a memory. The medicine prize has, in recent years, gone to vaccines, immune checkpoints and microRNA. This one goes to a switch. The next five prizes of the week, physics through economics, will show whether 2026 stays with tools or returns to particles and markets.